| Biovest Meets Skeptic's Requirements for 'The Next Dendreon': Part 2 James Hill, MD submits: Part 1 of this series examined the emphasis Minyanville’s David Miller rightly places on manufacturing in determining whether a company can become a cancer vaccine success, like Dendreon (DNDN) has with the FDA’s recent approval of Provenge (sipuleucel-T). Besides Dendreon and Biovest (BVTI.PK), other companies are developing active immunotherapies for cancer. Celldex (CLDX) is working on a brain cancer vaccine. So is ImmunoCellular Therapeutics (IMUC.OB). Same for Antigenics' (AGEN) Oncophage, for recurrent high-grade glioma. GlaxoSmithKline (GSK) is conducting the largest ever phase 3 clinical trial for lung cancer with its MAGE-A3 treatment.Complete Story » seekingalpha.com |
Generic Lovenox Wins Approval The FDA approved the first generic version of the big-selling blood thinner Lovenox, in a victory for a unit of Novartis. online.wsj.com |
Chairman and Chief Scientist at ERT Recognized as One of 100 Most Inspiring People in the Life Sciences Industry (PR Newswire) ERT , a leading provider of centralized services to global pharmaceutical, biotechnology and medical device companies, announces that Joel Morganroth, MD, Chairman and Chief Scientist, has been acknowledged by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry. Â Dr. us.rd.yahoo.com |
Can Array BioPharma Attract Yet Another Partner? M.E. Garza submits: By Patrick Crutcher Shares of Array BioPharma Inc.(NASDAQ:ARRY) traded up after announcing positive interim results of its novel, oral HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in patients with advanced cancer. The results presented at the 2010 ASCO Breast Cancer Symposium in National Harbor, Maryland, may attract some attention to the company going forward. ARRY-380 is a potent, orally active small molecule drug that has been well-tolerated to date and selectively inhibits tumor growth in preclinical models of HER2-dependent tumors. HER2, also known as ErbB2, is a receptor tyrosine kinase that has been found to be over-expressed in breast cancer and other cancers such as gastric and ovarian. ARRY-380 has demonstrated significant dose-related tumor growth inhibition in preclinical models that was superior to Herceptin and Tykerb(lapatinib) and was additive for tumor growth inhibition in preclinical models when dosed in combination with the standard of care therapeutics such as Herceptin(trastuzumab) or Taxotere(docetaxel). Ideally, ARRY-380 would be competing with Herceptin, which is a blockbuster drug for Genentech (DNA).Complete Story » seekingalpha.com |
Alere Inc. Schedules Conference Call for 10:00 a.m. ET November 1, 2010 to Discuss Third Quarter 2010 Results [PR Newswire] - Alere Inc. , a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced that it will release its third quarter 2010 earnings on Monday, November 1, 2010. us.rd.yahoo.com |